P2Y purinoceptors as potential emerging therapeutical target in vascular disease.
P2Y purinoceptors as potential emerging therapeutical target in vascular disease.
复制标题
DOI：
10.2174/138161212803582504
复制
发表时间：
2012-11
影响因子：
3.1
通讯作者：
M. Schuchardt;M. Tölle;M. van der Giet
中科院分区：
文献类型：
--
作者：
M. Schuchardt;M. Tölle;M. van der Giet
在过去的二十年中，我们对嘌呤能系统的理解有了巨大的发展，嘌呤能系统由异质表达的嘌呤受体亚型及其经典激动剂组成，如三磷酸腺苷、三磷酸尿苷或复合二核苷多磷酸。这些激动剂对血管系统发挥多重作用：它们调节动脉血管的舒张和收缩，导致内皮细胞和血管平滑肌细胞的增殖和迁移，介导强效的促炎反应或细胞表型改变。本文综述了P2嘌呤受体亚型P2Y及其在生理和病理生理条件下对血管壁的多效性作用。各种实验和临床研究证明，P2Y的药理靶向可能有效地减少疾病条件下的血管改变。
In the last two decades a tremendous development has been noticed in our understanding of the purinergic system, consisting of heterogeneously expressed purinoceptor subtypes and its classical agonists: e.g., adenosine triphosphate, uridine triphosphate or complex dinucleoside polyphosphates. These agonists exert multiple effects on the vascular system: they regulate the relaxation and constriction of arterial blood vessels, lead to proliferation and migration in endothelial cells and vascular smooth muscle cells, and mediate potent proinflammatory responses or phenotypic cell changes. This review focuses on the P2 purinoceptor subtype P2Y and its pleiotropic effects in the vascular wall under physiological and pathophysiological condition. Various experimental and clinical studies provide evidence that pharmacological targeting of P2Y might be effective in reducing vascular alterations under disease conditions.